Approximately fifty percent of MM patients with AKI who respond to bortezomib-based regimens will have a resulting significant improvement in renal function within a few weeks after therapy initiation.[ 1 , 2 , 25 ] It is possible that the findings did not reach statistical significance because of the limited number of patients treated without novel agents.
← all excerpts
Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study.
2
—
—
The sentences
Nevertheless, the corresponding one-year survival rates showed a trend toward being higher in the HCO-HD group (69%) than in the conv.